The use of vancomycin powder in total elbow arthroplasty; can we decrease infection risk?
The use of IVP was associated with almost half the risk of developing a PJI during primary TEA (13.6% vs. 7.7%). However, this was not statistically significant, likely due to underpowering with a relatively small sample size of patients receiving IVP. The reduction in PJI seen in this IVP cohort has still changed the practice of the authors, who now routinely administer vancomycin powder for total elbow arthroplasty.
Authors
- Nainisha Chintalapudi (ORCID: https://orcid.org/0000-0003-4531-599X)
- Kennedy Gachigi
- Blake H. Hodgens (ORCID: https://orcid.org/0000-0002-1757-5324)
- Bryan J. Loeffler (ORCID: https://orcid.org/0000-0002-7718-7825)
- R. Glenn Gaston
- Maria S. Kammire (ORCID: https://orcid.org/0000-0002-3357-0697)
- Olusola Omonije
Institutions
- Institute for Musculoskeletal Health (AU)
- OrthoCarolina (US)
- OrthoCarolina Research Institute (US)
- Carolina Musculoskeletal Institute (US)
Publication Details
- Journal
- JSES Reviews Reports and Techniques
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1016/j.xrrt.2025.06.013
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00